Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Hematology. 2022 Dec;27(1):343-352. doi: 10.1080/16078454.2022.2045724.
Treatment strategies for relapsed/refractory MM are particularly complex. In particular, patients who are refractory to the three classes of therapies have limited therapeutic options and poor survival. Fortunately, promising treatments are emerging, but their incorporation into existing treatments still needs to be defined. We will describe the latest trends and emerging developments in the field of therapies for RRMM by analyzing the most recent clinical data and new technologies in drug development.
Pubmed, Embase and Cochrane Library were searched to select eligible studies, the clinical data of new promising treatments were reviewed. key the most recent clinical trial .
A total of 13 studies were included in the final analysis involving anti-BCMA CAR T-cell therapy, Combined CAR T-cell therapy, antibody-drug conjugates, bispecific Ab therapy and CELMoDs. The key efficacy and side effects of treatments were summarized.
There is great promise for a set of next-generation of rescue therapies, including CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates, and novel PROteolysis Targeting Chimeras. Emerging new treatments for MM provide more choices for relapsed/refractory multiple myeloma (RRMM). The optimal therapy for each patient should be based on disease-related factors, such as previous therapies, duration of response to prior drugs, clinical and biochemical features of relapse, and the relationship of patient comorbidities with known AE profiles of the different therapies.
复发/难治性多发性骨髓瘤（RRMM）的治疗策略特别复杂。特别是对三类治疗药物均耐药的患者，治疗选择有限，生存状况较差。幸运的是，一些有前景的治疗方法正在出现，但如何将其纳入现有的治疗方案仍需进一步明确。我们将通过分析最新的临床数据和药物研发的新技术，来描述 RRMM 治疗领域的最新趋势和新兴发展。
检索了 Pubmed、Embase 和 Cochrane Library 以选择符合条件的研究，综述了新的有前景的治疗方法的临床数据。重点分析了最新的临床试验。
共有 13 项研究最终纳入分析，涉及抗 BCMA CAR T 细胞疗法、联合 CAR T 细胞疗法、抗体药物偶联物、双特异性 Ab 疗法和 CELMoDs。总结了治疗方法的关键疗效和副作用。
一组下一代挽救治疗方法具有很大的应用前景，包括 CAR T 细胞疗法、双特异性抗体、抗体药物偶联物和新型 PROteolysis 靶向嵌合体。新兴的 MM 治疗方法为复发/难治性多发性骨髓瘤（RRMM）提供了更多的选择。每位患者的最佳治疗方案应基于疾病相关因素，如既往治疗、对既往药物的反应持续时间、复发的临床和生化特征，以及患者合并症与不同治疗方法已知不良反应谱的关系。
